Enter your email address below and subscribe to our newsletter

Research & Studies

Share your love

MCG Secures $1.5M Grant for New Diabetic Retinopathy Therapy

Researchers at the Medical College of Georgia (MCG) at Augusta University have been awarded a $1.5 million grant from the National Eye Institute to develop a new treatment for diabetic retinopathy, a leading cause of blindness. Diabetic retinopathy results from…

Trinity College Develops Gene Therapy for Glaucoma and AMD

A team of researchers at Trinity College Dublin has developed a gene therapy that shows promise for treating both glaucoma and dry age-related macular degeneration (AMD). The therapy, which uses an enhanced gene (eNdi1) delivered by an approved virus, aims…

Oculus Introduces Pentacam Cornea OCT at ESCRS 2024

Oculus has unveiled the Pentacam Cornea OCT, an innovative device that integrates Scheimpflug imaging with the world’s first pericentric OCT scanning system. This dual imaging technology captures both Scheimpflug and ultra high-resolution OCT images of the cornea in just one…

Dangers of Eye Color-Changing Drops: Ophthalmologists Warn

The American Academy of Ophthalmology is warning the public about over-the-counter eye drops that claim to change eye color. These products, popularized on social media platforms like TikTok, are unproven, unregulated, and could pose significant risks to eye health. Unapproved…

Opus Genetics Receives FDA RPD Designation for OPGx-LCA5

Research Triangle Park, N.C. – August 20, 2024 – Opus Genetics has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for its ocular gene therapy, OPGx-LCA5, which aims to treat patients with…

AMD Explained: Tips for Safeguarding Your Vision

The eyes are often called the windows to the soul, but what happens when those windows become cloudy and blurred? That’s the reality for millions suffering from age-related macular degeneration (AMD), which can rob you of your precious eyesight as…

European Commission Approves Roche’s Vabysmo for RVO

The European Commission has approved Roche’s Vabysmo® (faricimab) for the treatment of macular edema secondary to retinal vein occlusion (RVO), including both branch and central retinal vein occlusion (BRVO and CRVO). This approval is a significant milestone, making Vabysmo the…

Stay informed and not overwhelmed, subscribe now!